The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.Novo Nordisk on Wednesday flagged promising late-stage trial results for its new Cagrilinitide obesity treatment, as the Danish pharmaceutical giant seeks a next-generation alternative to its blockbuster Wegovy weight-loss drug.Early analysis from a phase ...